VBL Therapeutics Announces First Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles up 2% after Trump rejects return to Iran ceasefire deal terms
- Could SpaceX's orbital compute avoid the political headwinds facing data centers?
- Could Meta's teen settlement be less painful than feared? Citi weighs in
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Ovintiv adds 41,000 acres in Permian and Montney deals
- Rubrik (RBRK) Tops Q2 EPS by 16c, Beats on Revenue; Offers FY27 EPS Guidance
Vascular Biogenics (VBLT) Tops Q1 EPS by 8c
May 12, 2015 8:55 AM EDTVascular Biogenics (NASDAQ: VBLT) reported Q1 EPS of ($0.15), $0.08 better than the analyst estimate of ($0.23).
Cash, cash equivalents and short term deposits as of March 31, 2015 were $34.4 million, compared to $36.8 million at year end 2014.
For earnings history and earnings-related data on Vascular Biogenics (VBLT) click here.
... More